Egalet Corporation (NASDAQ:EGLT) Weekly Ratings on May 16, 2018

May 16, 2018 - By Madeline Delgado

Egalet Corporation (NASDAQ:EGLT) Corporate Logo
During Q4 2017 the big money sentiment decreased to 0.47. That’s change of 0.11, from 2017Q3’s 0.58. 13 investors sold all, 17 reduced holdings as Egalet Corporation ratio is negative. 8 rose stakes while 6 funds took stakes. Funds hold 13.62 million shares thus 32.80% less from 2017Q3’s 20.27 million shares.
Balyasny Asset Management Ltd Com accumulated 23,147 shs or 0% of the stock. Nj State Employees Deferred Compensation Plan owns 230,000 shs. Royal Bancorp Of Canada invested 0% in Egalet Corporation (NASDAQ:EGLT). Janney Montgomery Scott Ltd Liability holds 0% or 22,159 shs in its capital. Franklin, California-based fund reported 2.73M shs. Northern reported 97,109 shs. Morgan Stanley invested in 3,410 shs or 0% of the stock. The Pennsylvania-based Vanguard Grp has invested 0% in Egalet Corporation (NASDAQ:EGLT). D E Shaw reported 299,312 shs stake. California Public Employees Retirement Systems invested 0% of its capital in Egalet Corporation (NASDAQ:EGLT). Barclays Plc holds 65 shs or 0% of its capital. Msd Prns Lp holds 0.05% or 1.04M shs in its capital. Geode Cap Management Ltd Liability reported 67,633 shs stake. Pnc Services Group Inc stated it has 400 shs. Virtu Limited accumulated 11,259 shs.

Egalet Corporation (NASDAQ:EGLT) Ratings Coverage

In total 2 analysts cover Egalet (NASDAQ:EGLT). “Buy” rating has 0, “Sell” are 0, while 2 are “Hold”. (NASDAQ:EGLT) has 0 bullish analysts. 3 are the (NASDAQ:EGLT)’s ratings reports on May 16, 2018 according to StockzIntelligence Inc. On Wednesday, January 3 the stock of Egalet Corporation (NASDAQ:EGLT) has “Hold” rating given by Stifel Nicolaus. On Tuesday, May 8 the company was downgraded by Cantor Fitzgerald. On Monday, March 12 the firm earned “Buy” rating by Cantor Fitzgerald. Listed here are Egalet Corporation (NASDAQ:EGLT) PTs and latest ratings.

08/05/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $1.5000 Downgrade
12/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $3.5 Maintain
03/01/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Hold Downgrade

EGLT reached $0.5 during the last trading session after $0.06 change.Egalet Corporation has 2.09 million shares volume, 142.29% up from normal. EGLT is downtrending and has moved 87.31% since May 16, 2017. The stock underperformed the S&P500 by 98.86%.

Egalet Corporation, a specialty pharmaceutical company, develops, makes, and commercializes treatments for patients with pain and other conditions.The firm is worth $26.43 million. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic moderate to severe pain where an opioid is appropriate; and ARYMO ER, an extended-release morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.Currently it has negative earnings. The firm is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER.

There’s a significant Egalet Corporation (NASDAQ:EGLT) news brought out by Seekingalpha.com. It’s a report titled: “Egalet’s (EGLT) CEO Bob Radie on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018.

Egalet Corporation (NASDAQ:EGLT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.